[Prevention of thromboembolism with low molecular weight heparin (Fragmin) in obstetrics].
A total of 130 obstetrical patients were treated with either low molecular weight (LMW) or unfractionated (UFH) heparin as part of prospective study comparing their efficacy in the prevention of thromboembolism. A single daily dose of 2500-5000 anti-Xa-units LMW heparin (Fragmin) or two to three daily doses of 5000 IU UFH (Liquemin) were given to two groups of 15 patients with therapeutic tocolysis and 50 patients with cesarean section. Patients with cesarean section were given 500 ml Dextran 60 i.v. during surgery followed by subcutaneous injection of heparin eight to ten hours after surgery. Heparin therapy was continued for ten days after surgery. None of the patients exhibited clinical signs of thrombosis. The majority of patients showed symptoms of local irritation at the site of heparin injection (69% of patients with LMW heparin; 80% of patients with UFH). Hematomas at the site of injection were significantly smaller when LMW heparin was used instead of UFH. A number of patients experienced headache after heparin application (10% of patients with LMW heparin; 13% of patients with UFH). There were no cases of post surgical haemorrhage. Comparison of daily profiles revealed a significantly higher anti-Xa-activity of LMW heparin compared to UFH. In contrast, other coagulation parameters were not different in the two experimental groups (antithrombin III, partial thrombin time, thrombin time). Hematologic parameters and liver enzymes were in the physiological range in both experimental groups and none of the patients exhibited signs of heparin induced thrombocytopenia.(ABSTRACT TRUNCATED AT 250 WORDS)
Krauss
T
T
Universitäts-Frauenklinik Göttingen.
Rath
W
W
Dittmer
U
U
Kuhn
W
W
D000293:Adolescent; D000328:Adult; D001780:Blood Coagulation Tests; D002585:Cesarean Section; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005312:Fetal Blood / Q000187:drug effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D011183:Postoperative Complications / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013923:Thromboembolism / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D015145:Tocolysis; D016896:Treatment Outcome
D006495:Heparin, Low-Molecular-Weight
Thromboembolieprophylaxe mit niedermolekularem Heparin (Fragmin) in der Geburtshilfe.